CSF2 and pulmonary alveolar proteinosis: Gene therapy for PAP may offer some advantages over recombinant protein-based treatment, including less frequent dosing, higher local GM-CSF levels, and a more stable steady-state concentration profile, which may further enhance the therapeutic index.